AbbVie wins $56M royalty award from Revance in Botox patent infringement case

22nd July 2025 Uncategorised 0

A Delaware jury has agreed with AbbVie’s claim that in creating a rival treatment for Botox, Revance Therapeutics infringed on three patents covering the formulation and manufacturing process of the mega-blockbuster. With the verdict, the jury awarded a royalty payment of $56 million from Revance to AbbVie.

More: AbbVie wins M royalty award from Revance in Botox patent infringement case
Source: fierce